Clinical Trial

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Recruiting
View on ClinicalTrials.gov →
Summary
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Protocol Amendment History 1 change
notable Trial sites expanded: 88 -> 91 locations 2026-05-27
Trial Details
NCT Number NCT07284121
Lead Sponsor Hoffmann-La Roche
Conditions Lung Cancer, Hepatocellular Carcinoma
Enrollment 700 participants
Start Date 2025-07-15
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-17